| |
Learn how Transmission Electron Microscopy (TEM) enables precise quantification of virus-like particles (VLPs) in unprocessed bulk material. Discover the importance of TEM in viral safety testing and cell line characterization. Check out our scientific poster!
|
|
Today’s Big NewsOct 21, 2024 |
|
Wednesday, October 29, 2024 | 11am ET / 8am PT Real-world data is essential to gaining insights into a patient’s diagnostic journey. However, many pharma companies may not be using lab data to its full potential. Join us to discuss how today’s robust lab data sources can help improve patient access and time to treatment, leading to better patient outcomes. Register now.
|
|
| By Nick Paul Taylor Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to sustained suppression of the virus out to 48 weeks in a midphase clinical trial. |
|
|
|
By Kevin Dunleavy Sanofi is now in “exclusive negotiations" with U.S. private equity firm Clayton, Dubilier & Rice to sell a 50% controlling stake in its consumer health business Opella, the company said. The deal values the consumer group at 16 billion euros. |
By Conor Hale Intuitive reported an 18% increase in procedure volume compared to last year's third quarter, driven by a worldwide base of about 9,500 systems. |
By Angus Liu After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S. drug cost watchdog has provided a final analysis that includes a smaller—yet still hefty—price reduction demand. |
By Kevin Dunleavy Two years after emerging with its initial funding round, CDMO Nucleus RadioPharma is going bicoastal, revealing expansions at two sites that the company believes will "significantly improve” market access to the promising cancer treatments. |
By James Waldron After launching on its maiden voyage in April, Seaport Therapeutics and its crew of Karuna veterans have loaded up with $225 million in series B funds to support the journey to key clinical milestones for its neuropsychiatric medicines. |
By Angus Liu As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too. |
By Nick Paul Taylor Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match a Vicodin equivalent in one of the studies. |
By Conor Hale Boston Scientific collected a set of FDA green lights allowing it to combine cardiac mapping sensors and pulsed field ablation delivery in a single catheter. |
By Fraiser Kansteiner As part of a new round of layoffs, certain Takeda staffers at two Massachusetts sites are set to lose their jobs. This marks the third round of job cuts Takeda has initiated in the state since it revealed a large restructuring drive in May. |
By James Waldron Septerna may still be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor appetite for its G protein-coupled receptors. |
By Conor Hale The Malibu, California-based company’s series A round was led by ExSight Ventures and included backing from Main Street Advisors and the UC Investments arm of the University of California system. |
Fierce podcastsDon’t miss an episode |
| In this week’s episode of “The Top Line,” we catch up with three past Fierce 15 honorees to gain their insights, experiences and visions for the evolving biotech landscape. |
|
|---|
|
|
|
Thursday, November 14, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now.
|
|
| WhitepaperDiscover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
| eBookNeed the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
| WhitepaperTake a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
| WhitepaperUnlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
